Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

127.07 -0.18 (-0.14%)
Streaming Delayed Price Updated: 9:43 AM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
47 48 Next >
Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication
The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS)... 
Via Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis
 
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novartis To Strengthen Pipeline, Boost Productivity With New Organizational Structure
 
Via Benzinga
FDA Approves Novartis' Pluvicto As First Targeted Radioligand Therapy For Prostate Cancer
 
Via Benzinga
Novartis Suspends Some Investment, Business Activities In Russia
 
Via Benzinga
Morning Brief: Top Stories Dominating Financial Media on Monday, April 4
Reuters ExxonMobil Ditches Russia Following Western Sanctions Exxon Mobil Corp (NYSE: XOM) suspended its liquefied natural gas project in Russia’s Far East following... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
Rx Holdings Acquires Biocel Access Solutions
A Strategic Initiative That Taps Into the $8.4 Billion Affordability Market 
Via Newswire.com
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China. 
Via InvestorPlace
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
Novartis Receives Positive CHMP Opinion For Kymriah In Follicular Lymphoma, Jakavi In GvHD
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Novartis AG's (NYSE: NVS)  
Via Benzinga
Flood Helping Ukraine
Emerging markets are gaining as mature markets look risky. 
Via Talk Markets
This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Pharmacovigilance (PV) Outsourcing Market Size, Share, Trends, Industry Analysis, Growth and Forecast 2022-2028
Pharmacovigilance (PV) Outsourcing Market 2022-2028, Segmentation, Swot Analysis including Key Players like – Accenture, C3i Solutions, Clintec, Covance, ELC Group, Ergomed, IQVIA, Novartis, Parexel 
Via SBWire
This Company Is Making Progress In Its Fight Against Rare, Terminal Cancers
Photo by National Cancer Institute on Unsplash 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Morning Brief: Top Stories Dominating Financial Media on Tuesday, March 22
CNBC 
Via Benzinga
Lucky Day
Today Alleghany rose nearly 25% because it is being bought by Berkshire Hathaway, Warren Buffett's fund. 
Via Talk Markets
Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study
Novartis AG (NYSE: NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment for spinal... 
Via Benzinga
Biogen Posts New Updates Across its Spinraza SMA Research Program
Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and... 
Via Benzinga
Why Another ADHD Stimulant? Cingulate Inc. Believes It's All About The Timing
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. People diagnosed with attention... 
Via Benzinga
Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat
Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO... 
Via Benzinga
Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead, Orbsen, and Others
Continue reading "Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead,... 
Via Get News
NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting
The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG's (NYSE: NVS) Kisqali (ribociclib) plus letrozole... 
Via Benzinga
7 Drug Stocks to Consider After the Viatris Plunge
As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market. 
Via InvestorPlace
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs
Novartis AG (NYSE: NVS) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR) for three capsids to use in potential gene... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
47 48 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.